免疫療法のためのマクロファージの遺伝子組換え

Japanese Patent JP7298103

B2

Disclosed are methods of making a genetically modified immune cell for modifying a tumor microenvironment (TME) and methods of modifying a tumor microenvironment (TME). In some embodiments, the method can include delivering a first vector to an immune cell, wherein the first vector comprises a nucleic acid encoding a protein that induces T-cell proliferation, promotes persistence and activation of endogenous or adoptively transferred NK or T cells and/or induces production of an interleukin, an interferon, a PD-1 checkpoint binding protein, HMGB1, MyD88, a cytokine or a chemokine. Methods of modulating the suppression of the immune response in a tumor microenvironment, minimizing the proliferation of tumor and suppressive cells, and increasing the efficiency of an anti-cancer therapy, anti-infection therapy, antibacterial therapy, anti-viral therapy, or anti-tumoral therapy are also provided.

Crane, Courtney
Jensen, Michael, Shee.
White Moise, Kara
Lieberman, Nicole

JP2021075261A

June 27, 2023

April 27, 2021

Click for automatic bibliography generation  

Seattle Children's Hospital (DBA Seattle Children's Research Institute)

C12N5/10; A61K35/15; A61K38/19; A61K38/20; A61K38/21; A61K39/395; A61K48/00; A61P35/00; A61P37/04; A61P43/00; C12N15/09

US20120003220
WO2014201212A1

Cancer Gene Ther.,1995年,Vol.2, p.113-124
Cancer research,2003年,Vol.63,p.7853-7860
Gene Therapy,2013年,Vol.20, p.514-520
Clinical Cancer Research,2013年,vol.19,p.3165-3175
Science,2014年,Vol.343,p.84-87

Ryu Iwatani

Previous Patent: Magnetic bead purification system

Next Patent: Chest compressions following chest compliance